Francois Paris

Summary

Affiliation: CHU de Nantes
Country: France

Publications

  1. doi request reprint Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial
    Françoise Kraeber-Bodéré
    University Hospital, Nantes, France Institut de Cancérologie de l Ouest Cancer Center, Saint Herblain, France Electronic address
    Lancet Haematol . 2016
  2. pmc Tumor immunotargeting using innovative radionuclides
    Françoise Kraeber-Bodéré
    Nantes Angers Cancer Research Center CRCNA, University of Nantes, INSERM UMR 892, CNRS UMR 6299, Nantes 44007, France
    Int J Mol Sci 16:3932-54. 2015
  3. doi request reprint Radioimmunoconjugates for the treatment of cancer
    Françoise Kraeber-Bodéré
    Centre de recherche en cancérologie de Nantes Angers, INSERM, Universite de Nantes, Nantes, France Department of Nuclear Medicine, CHU de Nantes, Nantes, France Department of Nuclear Medicine, ICO René Gauducheau, Saint Herblain, France Electronic address
    Semin Oncol 41:613-22. 2014
  4. pmc Improvement of radioimmunotherapy using pretargeting
    Eric Frampas
    Radiology Department, University Hospital, Nantes Cedex, France Le Centre Régional de Recherche en Cancérologie Nantes Angers, Centre National de la Recherche Scientifique, Universite de Nantes, Nantes Cedex, France
    Front Oncol 3:159. 2013
  5. pmc Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT
    Thomas Carlier
    Nuclear Medicine Department, University Hospital of Nantes, Place Alexis Ricordeau, Nantes, 44093, France
    EJNMMI Res 3:11. 2013
  6. pmc Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors
    Caroline Rousseau
    Centre de recherche en cancérologie de Nantes Angers, Universite de Nantes, INSERM, U892, Nantes, France
    EJNMMI Res 1:20. 2011
  7. doi request reprint Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, University Hospital ICO INSERM UMR 892, Nantes, France
    J Nucl Med 53:1836-46. 2012
  8. doi request reprint Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC)
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, University Hospital, ICO René Gauducheau, Nantes, France
    Tumour Biol 33:601-6. 2012
  9. ncbi request reprint Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, Rene Gauducheau Cancer Center, Nantes, France
    J Nucl Med 47:247-55. 2006
  10. doi request reprint Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft
    Françoise Kraeber-Bodéré
    INSERM UMR 892 Cancer Research Center, Universite de Nantes, Nantes, France
    J Nucl Med 51:624-31. 2010

Collaborators

Detail Information

Publications31

  1. doi request reprint Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial
    Françoise Kraeber-Bodéré
    University Hospital, Nantes, France Institut de Cancérologie de l Ouest Cancer Center, Saint Herblain, France Electronic address
    Lancet Haematol . 2016
    ....
  2. pmc Tumor immunotargeting using innovative radionuclides
    Françoise Kraeber-Bodéré
    Nantes Angers Cancer Research Center CRCNA, University of Nantes, INSERM UMR 892, CNRS UMR 6299, Nantes 44007, France
    Int J Mol Sci 16:3932-54. 2015
    ....
  3. doi request reprint Radioimmunoconjugates for the treatment of cancer
    Françoise Kraeber-Bodéré
    Centre de recherche en cancérologie de Nantes Angers, INSERM, Universite de Nantes, Nantes, France Department of Nuclear Medicine, CHU de Nantes, Nantes, France Department of Nuclear Medicine, ICO René Gauducheau, Saint Herblain, France Electronic address
    Semin Oncol 41:613-22. 2014
    ..Personalized treatments, based on quantitative positron emission tomography (PET), pre-therapeutic imaging, and dosimetry procedures, also could be applied to adapt injected activity to each patient. ..
  4. pmc Improvement of radioimmunotherapy using pretargeting
    Eric Frampas
    Radiology Department, University Hospital, Nantes Cedex, France Le Centre Régional de Recherche en Cancérologie Nantes Angers, Centre National de la Recherche Scientifique, Universite de Nantes, Nantes Cedex, France
    Front Oncol 3:159. 2013
    ..The following review addresses actual technical and clinical considerations and future development of pRIT. ..
  5. pmc Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT
    Thomas Carlier
    Nuclear Medicine Department, University Hospital of Nantes, Place Alexis Ricordeau, Nantes, 44093, France
    EJNMMI Res 3:11. 2013
    ..The aim of this work was to determine the minimum detectable activity (MDA) of 90Y by PET imaging and the impact of time-of-flight (TOF) reconstruction on detectability and quantitative accuracy according to the lesion size...
  6. pmc Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors
    Caroline Rousseau
    Centre de recherche en cancérologie de Nantes Angers, Universite de Nantes, INSERM, U892, Nantes, France
    EJNMMI Res 1:20. 2011
    ....
  7. doi request reprint Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, University Hospital ICO INSERM UMR 892, Nantes, France
    J Nucl Med 53:1836-46. 2012
    ....
  8. doi request reprint Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC)
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, University Hospital, ICO René Gauducheau, Nantes, France
    Tumour Biol 33:601-6. 2012
    ....
  9. ncbi request reprint Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, Rene Gauducheau Cancer Center, Nantes, France
    J Nucl Med 47:247-55. 2006
    ....
  10. doi request reprint Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft
    Françoise Kraeber-Bodéré
    INSERM UMR 892 Cancer Research Center, Universite de Nantes, Nantes, France
    J Nucl Med 51:624-31. 2010
    ..This study evaluated the toxicity and efficacy of combining radioimmunotherapy with thalidomide or a cyclopeptidic vascular endothelial growth inhibitor (CBOP11) in mice grafted with the TT human medullary thyroid cancer cell line...
  11. doi request reprint Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, Cancer Research Center, University Hospital, University of Nantes, Institut de Biologie, 9 quai Moncousu, Nantes, France
    Cancer 116:1118-25. 2010
    ..Pretargeted radioimmunotherapy has been the only innovative treatment modality convincingly showing some survival benefit when compared with a historical untreated control group...
  12. doi request reprint Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma
    Pierre Yves Salaun
    Nuclear Oncology Department, Cancer Research Center, INSERM U892, Universite de Nantes, Nantes, France
    Cancer 116:1053-8. 2010
    ..The present pilot study evaluated toxicity and efficacy of RIT combined with bevacizumab in mice subcutaneously grafted with TT MTC cells...
  13. pmc Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development
    Ariane Desselle
    INSERM, UMR892, Nantes, France
    PLoS ONE 7:e45423. 2012
    ..Our study demonstrates that Gb3 is a viable alternative target for immunotherapy and angiogenesis inhibition...
  14. doi request reprint Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo
    Denis Cochonneau
    INSERM U 892, Centre de recherche en cancérologie de Nantes Angers, Institut de Recherche en Santé de l Université de Nantes, 8 quai Moncousu, F 44007 Nantes cedex 1, France
    Cancer Lett 333:194-204. 2013
    ..Such a study represents a useful framework to optimize immunotherapy with O-acetyl-GD2-specific antibody in combination with chemotherapeutic agents...
  15. doi request reprint Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis
    Stéphanie Bonnaud
    Inserm UMR892 Centre de Recherche en Cancérologie Nantes Angers, Nantes, France
    Cancer Res 70:9905-15. 2010
    ..Our results provide strong pharmacologic and mechanistic proofs that S1P protects endothelial cells against acute radiation enteropathy...
  16. pmc Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside
    Julien Fleurence
    INSERM U892, Centre de recherche en cancérologie de Nantes Angers, Institut de Recherche en Santé de l Université de Nantes, Nantes, France
    Oncotarget 7:41172-41185. 2016
    ..Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas...
  17. pmc Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia
    Mickael Terme
    ATLAB Pharma, Institut de Recherche en Santé de l Université de Nantes, Nantes, France Inserm U 892, Centre de recherche en cancérologie de Nantes Angers, Institut de Recherche en Santé de l Université de Nantes, Nantes, France CNRS 6299, Centre de recherche en cancérologie de Nantes Angers, Institut de Recherche en Santé de l Université de Nantes, Nantes, France
    PLoS ONE 9:e87210. 2014
    ..Thus, new strategies are needed for the development of treatment intensification strategies to improve the outcome of these patients...
  18. ncbi request reprint Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen
    Nidia Alvarez-Rueda
    INSERM, Universite de Nantes, Nantes Atlantique Universités U601, Département de Recherche en Cancérologie, 9 quai Moncousu, F 44093 Nantes, France
    Clin Cancer Res 13:5613s-5620s. 2007
    ..We previously generated a mouse monoclonal antibody (mAb) specific for the tumor-associated GD2 ganglioside antigen. Here, we describe the development of a chimeric anti-GD2 mAb for more effective tumor immunotherapy...
  19. pmc A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity
    Nidia Alvarez-Rueda
    Centre de recherche en cancérologie de Nantes Angers, INSERM, Universite de Nantes, Nantes Atlantique Universites, U892, France
    PLoS ONE 6:e25220. 2011
    ..Hence, we investigated the distribution of OAcGD2 in human tissues using mAb 8B6 to study the cross-reactivity of mAb 8B6 with human tissues...
  20. doi request reprint Plasma ceramide, a real-time predictive marker of pulmonary and hepatic metastases response to stereotactic body radiation therapy combined with irinotecan
    Nolwenn Dubois
    institut de cancérologie de l Ouest, Saint Herblain, France INSERM, UMR892, Nantes, France Université de NANTES, France CNRS, UMR 6299, Nantes, France
    Radiother Oncol 119:229-35. 2016
    ..We evaluated the ability of ceramide, a bioactive sphingolipid, to predict tumour sensitivity in patients treated by hypofractionated stereotactic body radiation therapy (SBRT) combined with irinotecan chemotherapy...
  21. pmc Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling
    Emeline Brocard
    Centre de Recherche en Cancérologie Nantes Angers UMR INSERM 892, CNRS 6299, Universite de Nantes, 44007 Nantes, France
    Oncotarget 6:6840-9. 2015
    ..Indeed, PGE2 can substitute for EGF to promote primary cultures survival and growth in vitro and the effect is likely to occur though the Prostaglandin E2 receptor EP2. ..
  22. pmc Membrane signaling induced by high doses of ionizing radiation in the endothelial compartment. Relevance in radiation toxicity
    Isabelle Corre
    CRCNA UMR Inserm U892 CNRS 6299 Institut de Recherche en Santé de l Université de Nantes, Nantes 44007, France
    Int J Mol Sci 14:22678-96. 2013
    ..This review describes this signaling pathway and discusses the relevance of targeting endothelial signaling to protect healthy tissues from the deleterious effects of high doses of radiation...
  23. pmc Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review
    Mohammed Yahia Almaghrabi
    Department of Radiation Oncology, Integrated Oncology Centre, BD du Professeur Jacques MONOD, 44805, Saint Herblain, France
    Radiat Oncol 7:126. 2012
    ..SBRT of adrenal gland oligometastases shows promising results in the case of isolated lesions. In conclusion, properly conducted SBRT procedures are a safe and effective treatment option for abdominal oligometastases...
  24. pmc Improved functionality of the vasculature during conventionally fractionated radiation therapy of prostate cancer
    Vincent A Potiron
    INSERM, UMR892, Nantes, France Université de NANTES, Nantes, France CNRS, UMR6299, Nantes, France
    PLoS ONE 8:e84076. 2013
    ..Our results show that, in addition to tumor cell killing, vascular maturation plays an uncovered role in tumor reoxygenation during fractionated radiation therapy. ..
  25. doi request reprint RhoA GTPase regulates radiation-induced alterations in endothelial cell adhesion and migration
    Matthieu Rousseau
    Inserm UMR U892, Centre de Recherche en Cancérologie Nantes Angers CRCNA, Institut de Recherche Thérapeutique IRT UN, Universite de Nantes, 8 quai Moncousu, BP 70721, F 44007, France
    Biochem Biophys Res Commun 414:750-5. 2011
    ..These results highlight the role of RhoA GTPase in ionizing radiation-induced deregulation of essential endothelial functions linked to actin cytoskeleton...
  26. doi request reprint Oxidative stress disassembles the p38/NPM/PP2A complex, which leads to modulation of nucleophosmin-mediated signaling to DNA damage response
    Maëva Guillonneau
    Centre National de la Recherche Scientifique CNRS, Unité Mixte de Recherche 6299, Nantes, France INSERM, Unité Mixte de Recherche 892, Nantes, France Université de NANTES, Nantes, France and Le Centre de Recherche du Centre Hospitalier Universitaire de Québec Université Laval et le Centre de Recherche sur le Cancer de l Université Laval, Quebec City, Quebec, Canada
    FASEB J 30:2899-914. 2016
    ..Guillonneau, M., Paris, F., Dutoit, S., Estephan, H., Bénéteau, E., Huot, J., Corre, I. Oxidative stress disassembles the p38/NPM/PP2A complex, which leads to modulation of nucleophosmin-mediated signaling to DNA damage response. ..
  27. ncbi request reprint Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death
    Stéphanie Bonnaud
    Département de Recherche en Cancérologie, Institut National de la Sante et de la Recherche Medicale U601, Universite de Nantes, Faculte des Sciences, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 01, France
    Cancer Res 67:1803-11. 2007
    ....
  28. pmc Rapid Diminution in the Level and Activity of DNA-Dependent Protein Kinase in Cancer Cells by a Reactive Nitro-Benzoxadiazole Compound
    Viviane A O Silva
    UFIP CNRS UMR 6286, Mechanism and Regulation of DNA Repair Team, Faculte des Sciences et des Techniques, Universite de Nantes, 2 rue de la Houssiniere, 44322 Nantes, France
    Int J Mol Sci 17:. 2016
    ....
  29. doi request reprint Differentiation-related response to DNA breaks in human mesenchymal stem cells
    Lisa Oliver
    CRCNA INSERM UMR 892 CNRS UMR 6299, Nantes, France
    Stem Cells 31:800-7. 2013
    ..In addition, we observed a 95% recovery from DSB in these cells. Our results suggest that apoptosis and DNA repair are major safeguard mechanisms in the control of hMSCs differentiation after DNA damage...
  30. doi request reprint Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions
    Vincent A Potiron
    INSERM, UMR892, Nantes, France
    Radiother Oncol 106:138-46. 2013
    ..We investigated whether the novel PI3K/mTOR inhibitor BEZ235 might sensitize prostate cancer cells to radiation and reduce hypoxia-induced radioresistance...